Infection with herpes simplex virus type 1 (HSV-1) is common throughout the world, with many cases leading to symptomatic facial herpes. Following primary infection, HSV-1 establishes chronic latency, usually in the trigeminal ganglia, from where it reactivates periodically to cause recurrent outbreaks of infection. Recurrent facial herpes episodes vary in severity; they may be asymptomatic or appear as maculo-papular lesions that subsequently regress (abort), or vesicular lesions may develop which then scab prior to healing. Symptomatic lesions usually occur on the lips, cheeks, within the nose or on the nasal septum; they are often painful and unsightly. During asymptomatic or symptomatic outbreaks, HSV-1 is shed and thus there is a risk of transmission to susceptible individuals. Antiviral therapy in oral or topical formulations has been shown to be effective in treating facial herpes outbreaks. Oral therapy may also be used to suppress frequently recurring or severe episodes. For lesions at less readily accessible sites or when the risk of autoinoculation is high, oral therapy is warranted.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.